GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress
March 15 2023 - 9:00AM
via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a
biotechnology company developing immunotherapies and vaccines
against solid tumor cancers and infectious diseases, today
congratulates its colleague and collaborator, Don Diamond, Ph.D.
for recognition as a finalist for the Best Academic/Research Team
Award, part of the Vaccine Industry Excellence (ViE) Awards to be
held during the World Vaccine Congress in Washington, DC on April
3-6, 2023.
“Dr. Diamond and his team well-deserve this award and we are
proud to be collaborating with Don and his colleagues on the
clinical development of our next-generation COVID-19 vaccine
candidate, GEO-CM04S1,” stated David Dodd, GeoVax’s Chairman and
CEO. “GEO-CM04S1 resulted from research and development conducted
at City of Hope under Dr. Diamond’s leadership and is now a GeoVax
priority development program, progressing in two ongoing Phase 2
clinical trials. We applaud the foresight reflected in the
development of GEO-CM04S1 and look forward to the further
acceleration of the clinical program as it continues to expand to
multiple sites with interest worldwide.”
About GeoVax
GeoVax Labs, Inc. is a clinical-stage biotechnology company
developing novel therapies and vaccines for solid tumor cancers and
many of the world’s most threatening infectious diseases. The
company’s lead program in oncology is a novel oncolytic solid tumor
gene-directed therapy, Gedeptin®, presently in a multicenter Phase
1/2 clinical trial for advanced head and neck cancers. GeoVax’s
lead infectious disease candidate is GEO-CM04S1, a next-generation
COVID-19 vaccine targeting high-risk immunocompromised patient
populations. Currently in two Phase 2 clinical trials, GEO-CM04S1
is being evaluated as a COVID-19 vaccine for immunocompromised
patients such as those suffering from hematologic cancers and other
patient populations for whom the current authorized COVID-19
vaccines are insufficient. In addition, GEO-CM04S1 is in a Phase 2
clinical trial evaluating the vaccine as a more robust, durable
COVID-19 booster among healthy patients who previously received the
mRNA vaccines. GeoVax has a leadership team who have driven
significant value creation across multiple life science companies
over the past several decades. For more information, visit our
website: www.geovax.com.
Investor Relations Contact:Rich CockrellCG
Capital404-736-3838govx@cg.capital
GeoVax Labs (NASDAQ:GOVXW)
Historical Stock Chart
From Jun 2024 to Jul 2024
GeoVax Labs (NASDAQ:GOVXW)
Historical Stock Chart
From Jul 2023 to Jul 2024